Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data from a preclinical study evaluating the efficacy its NDV-3 vaccine in a model of vulvovaginal candidiasis (VVC), which is primarily caused by Candida albicans. The results were presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). NDV-3 is a prophylactic vaccine being developed for Candida and Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA), and recently completed a Phase 1 trial evaluating its safety and immunogenicity. NDV-3 is the first vaccine to demonstrate preclinical "cross-kingdom" protective efficacy against both fungal and bacterial pathogens.

The study concluded that vaccination with NDV-3 induced potent, protective immune responses against VVC that were characterized by high anti-NDV-3 antibodies. These immune responses led to decreases in vaginal fungal burden. The study found that the mechanism of protection elicited by NDV-3 against VVC was mediated by both T-cells and B-cells.

"This preclinical efficacy data for NDV-3 in a specific fungal disease indication further supports prior preclinical data, and also complements the positive immune response activity that NovaDigm recently reported from the Phase 1 trial for this vaccine," said Timothy Cooke, Ph.D., NovaDigm's Chief Executive Officer. "NDV-3 holds significant promise as a vaccine against VVC, which is one of the potential indications that NovaDigm is pursuing for this program."




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New vaccine targeting toxic Aβ may offer clinical benefit in treating Alzheimer's disease